The Cigna Group’s Stock Price Dips to $282.96, Marking a 3.76% Drop: A Review of CI’s Market Performance

The Cigna Group (CI)

282.96 USD -11.07 (-3.76%) Volume: 4.34M

The Cigna Group’s stock price stands at 282.96 USD, witnessing a drop of -3.76% this trading session with an active trading volume of 4.34M. The healthcare conglomerate’s year-to-date performance also reflects a downward trend with a percentage change of -3.28%.

Latest developments on The Cigna Group

Amid market shifts, Cigna Group stock hit a 52-week low at $288.86, following a trend of falling health insurance stocks like UnitedHealth Group. Despite a US$6.5 billion market value drop, institutional investors may overlook this as the company has seen a 6.7% return over the year. Cigna recently discontinued a ‘major’ Medicare Advantage plan in Montezuma County, contributing to the stock price movements. With appearances at events like the Bernstein Healthcare 1:1 Forum, Cigna remains a strong value stock, poised for growth despite industry challenges.

The Cigna Group on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely monitoring Cigna Group‘s performance. In a recent report titled “Cigna Corporation: Specialty Market Position & Biosimilars Strategy Driving Our Bullishness! – Major Drivers,” the analysts expressed a bullish sentiment. They highlighted Cigna Group‘s third-quarter 2024 earnings, which revealed a net income of $739 million or $2.63 per share. Despite a non-cash after-tax net realized investment loss of $1 billion related to VillageMD, the analysts excluded this from adjusted operating income and earnings per share.

In another report by Baptista Research titled “Cigna Corporation: Is Their Investment in VillageMD Yielding The Expected Results? – Major Drivers,” analysts discussed Cigna Group‘s first-quarter results for 2024. They noted the company’s financial strength and strategic advancements but also highlighted areas of setbacks and challenges. While there was an increase in revenue, adjusted earnings per share, and full-year 2024 earnings guidance, analysts cautioned that there are complexities that might affect Cigna’s future performance. Despite these challenges, the analysts maintained a bullish outlook on the company.

A look at The Cigna Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, the long-term outlook for Cigna Group appears to be positive. With high scores in Value and Dividend, the company is seen as a strong investment option for those looking for stable returns. While Growth, Resilience, and Momentum scores are slightly lower, indicating some areas for potential improvement, overall Cigna Group seems to be a solid choice for investors seeking a reliable insurance company.

The Cigna Group operates as an insurance company, offering a variety of insurance products and services to individuals, families, and businesses globally. With a focus on life, accident, disability, supplemental, medicare, and dental insurance, the company provides comprehensive coverage for a wide range of needs. Despite facing some challenges in terms of growth and momentum, Cigna Group‘s strong value and dividend scores suggest that it remains a stable and profitable entity in the insurance industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma